Replimune Group Inc.

REPL | NASDAQ

Price Alert Chart Builder DCF Calculator

$18.57

+$0.96 (+5.45%)

Nov 2, 2026, 12:30 PM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+5.45%

(1D)

No price chart data available for 1D timeframe.

Rating

Updated: Nov 2, 2026

+4.5 pts

Fundamentals Weak

Market Sentiment Neutral

Moat None

Sector Rank #847/1028 (Top 82%)

Full Analysis

Key Statistics

Market Data

Market Cap $1.76B

1D Range

17.67 18.61

52W Range

1.70 18.61

Valuation (TTM)

PE -6.31

PB 8.15

EV/EBITDA -5.75

Valuation (NTM)

Forward PE N/A

Forward PEG 0.22

Price Target $24.75

Cash Flow

FCF Yield -14.7%

SBC Adj. FCF Yield -16.7%

SBC Impact -13.6%

Margins

Gross Margin 0.0%

Operating Margin 0.0%

FCF Margin N/A

Growth (CAGR)

Revenue 3Y | 5Y N/A | N/A

Dil EPS 3Y | 5Y 5.4% | -1.1%

FCF 3Y | 5Y -12.3% | -19.7%

Returns

ROA -72.5%

ROE -157.8%

ROIC -80.9%

Financial Health

Net Cash

$208.07M

Current Ratio 7.11

Interest Coverage -22.53

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Replimune Group, Inc. is a biotechnology enterprise dedicated to pioneering oncolytic immuno-gene therapies aimed at treating various cancers. The company leverages its proprietary Immunotherapy platf...

Sector Healthcare

Industry Biotechnology

Employees 465

IPO Date Jul 20, 2018

Website www.replimune.com

Fiscal Year April - March

Full Company Profile

Latest News

6 hours ago · zacks.com

Wall Street Analysts Believe Replimune Group (REPL) Could Rally 26.8%: Here's is How to Trade

The mean of analysts' price targets for Replimune Group (REPL) points to a 26.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

4 days ago · fool.com

Replimune: 3 Key Takeaways for Long-Term Investors

Replimune ended the second quarter with $307.8 million in cash. Over 15 institutions wrote prescriptions within 20 business days.

4 days ago · seekingalpha.com

Replimune Group, Inc. (REPL) Q2 2027 Earnings Call Transcript

Replimune Group, Inc. ( REPL ) Q2 2027 Earnings Call October 28, 2026 8:00 AM EDT Company Participants Arleen Goldenberg Sushil Patel - CEO & Director Michelle DiNapoli - Chief Commercial Officer Emily Hill - Chief Financial Officer Conference Call Participants Evan Seigerman - BMO Capital Markets Equity Research Allison Bratzel - Piper Sandler & Co., Research Division Anupam Rama - JPMorgan Chase & Co, Research Division Jiale Song - Jefferies LLC, Research Division Mubeen Mosaheb Romy O'Connor - Van Lanschot Kempen NV Presentation Operator Good day, and thank you for standing by. Welcome to the Replimune's Second Quarter Fiscal 2027 Earnings Conference Call.

5 days ago · globenewswire.com

Replimune Reports Fiscal Second Quarter 2027 Financial Results and Provides Corporate Update

TUDRIQEV first delivered to patients for advanced melanoma on October 6th More than 15 institutions have prescribed TUDRIQEV Management will host a webcast today at 8:00 a.m. ET WOBURN, Mass.

11 days ago · globenewswire.com

Replimune to Report the Fiscal Second Quarter 2027 Financial Results and Provide Corporate Update on October 28, 2026

WOBURN, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a commercial stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that it will host a conference call on Wednesday, October 28, 2026, at 8:00 a.m. ET to discuss its financial results and provide corporate update for the fiscal second quarter ended September 30, 2026.

1 month ago · globenewswire.com

Replimune Announces TUDRIQEV™ Now Available in the U.S. for Advanced Melanoma

ReplimuneConnect Plus a comprehensive program that provides dedicated support and resources to help eligible patients access TUDRIQEV in the U.S. now live ReplimuneConnect Plus a comprehensive program that provides dedicated support and resources to help eligible patients access TUDRIQEV in the U.S. now live

2 months ago · seekingalpha.com

Replimune Group, Inc. (REPL) Shareholder/Analyst Call Prepared Remarks Transcript

3 months ago · globenewswire.com

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WOBURN, Mass., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a commercial stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the grant of inducement equity awards to Michelle DiNapoli, the Company's Chief Commercial Officer.

3 months ago · globenewswire.com

Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update

TUDRIQEV™ in combination with nivolumab receives FDA accelerated approval and will launch within 60 days Michelle DiNapoli appointed as Chief Commercial Officer Recently completed financing extends cash runway to support commercial launch and confirmatory trial WOBURN, Mass., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a commercial stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial results for the fiscal first quarter ended June 30, 2026 and provided a business update.